‘Alarming’ Overuse of Oral Corticosteroids in Severe Asthma Patients
A Canadian study found that 72% of patients with uncontrolled severe asthma were not on available biologic therapy, and 40% had four or more oral corticosteroid courses.
Tag: GSk
‘Alarming’ Overuse of Oral Corticosteroids in Severe Asthma Patients
A Canadian study found that 72% of patients with uncontrolled severe asthma were not on available biologic therapy, and 40% had four or more oral corticosteroid courses.
Read More
Arexvy RSV Vaccine Shows Protection Over Three Seasons
Cumulative efficacy over three RSV seasons was clinically meaningful at 62.9% against RSV-LRTD after a single dose of the vaccine.
Read More
GSK Clinches $1B Deal for Aiolos Bio and Its Investigational Asthma Therapy
GSK has agreed to acquire the startup biopharmaceutical company for $1 billion to access its investigational asthma treatment, AIO-001, ready to enter phase 2 clinical development.
Read More
FDA Panel to Convene to Review Promising RSV Vaccine Candidates
The FDA accepted Biologics License Applications and granted priority review for both Pfizer and GSK’s RSV older adult vaccine candidates last year following positive data from phase 3 trials.
Read More
GSK Sued Over Asthma Inhaler ‘Scheme’
Angling to block generics of Ventolin and Arnuity Ellipta, GSK for decades has “schemed” the FDA drug-device approval system to shield its asthma inhalers with patents and regulatory exclusivity, according to a proposed class-action complaint.
Read More
Breo Ellipta Gets FDA Approval for COPD
GlaxoSmithKline and Theravance Inc’s Breo Ellipta, an inhaled long-term, once-daily treatment for airflow obstruction in COPD patients, has received FDA approval.
Read More